Drug Trial Radar · NCT05174221
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Aug 16, 2022
Primary completion
Dec 15, 2025
Study completion Dec 15, 2025
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will have two parts. The main aims are to: * check the side effects from mezagitamab. * check for long-term side effects from mezagitamab. Before starting the study, participants will be asked to provide a 24-hour urine sample. A few weeks later, if enrolled they will begin receiving a subcutaneous injection (under the skin) of mezagitamab once a week for 8 weeks then once every 2 weeks for 16 weeks. When treatment has ended, there will be a 24-week follow-up period. Participants who receive benefit from the treatment may continue in the second part of the study where they will be monitored for up to 96 weeks and possibly retreated for another 24 weeks.
Conditions
- Kidney Disease
- Glomerulonephritis
Interventions
MezagitamabDrug
TAK-079 subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Study: Percentage of Participants With one or More Treatment-emergent Adverse Events (TEAEs), Grade 3 or Higher TEAEs, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Mezagitamab DiscontinuationTime frame: Up to Week 48
- LTE Observation Period: Percentage of Participants With one or More TEAEs, Grade 3 or Higher TEAEs and SAEsTime frame: Up to Week 96
- LTE Retreatment Period: Percentage of Participants With one or More TEAEs, SAEs, Grade 3 or Higher TEAEs and AEs leading to Mezagitamab DiscontinuationTime frame: Retreatment Week 0 to 48
Locations
26 sites in 11 countries. Site status is shown where the registry gives one.
Amicis Research Center - Northridge - Nordhoff
Northridge, California
Boise Kidney and Hypertension Institute - Frenova
Nampa, Idaho
NorthShore University HealthSystem
Evanston, Illinois
Core Research Group
Milton, Queensland, Australia
Monash Health, Monash Medical Centre
Clayton, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Beijing Friendship Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Semmelweis Egyetem
Budapest, Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, Csongrád megye, Hungary
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
Brescia, Lombardy, Italy
Kasugai Municipal Hospital
Kasugai-Shi, Aiti, Japan
Fujita Health University Hospital
Toyoake-shi, Aiti, Japan
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Sapporo City General Hospital
Sapporo, Hokkaido, Japan
National University Hospital- Singapore
Singapore, Singapore
Ajou University Hospital
Suwon, South Korea
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea
Hospital Universitario Vall d'Hebron - PPDS
Barcelona, Spain
Fundacio Puigvert
Barcelona, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Taipei Medical University Shuang Ho Hospital
New Taipei City, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Hull Royal Infirmary
Hull, United Kingdom
Leicester General Hospital
Leicester, Leicestershire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.